PANACRO refiles for Hong Kong listing on 20 August, digital-enabled clinical CRO

NewTimeSpace News: On 20 August 2026, PANACRO (Hangzhou) Pharmaceutical Consulting Co., Ltd. refiled its application for listing on the Hong Kong Stock Exchange, with China Industrial Securities International and ICBC International acting as joint sponsors. The Company is a clinical contract research organization (CRO) headquartered in Hangzhou, China, with its core business being the provision of clinical trial technical services to domestic and international pharmaceutical and biotechnology companies, aiming to accelerate the R&D and commercialization of chemical drugs and biological products. According to Frost & Sullivan, in 2025, the Company ranked 14th among companies headquartered in China by revenue from clinical CRO services, with a market share of 0.7%.

According to the announcement, by integrating digital systems into its clinical trial processes, the Company's proprietary digital infrastructure integrates its CTMS (Clinical Trial Management System), eTMF (Electronic Trial Master File) and CTFS (Clinical Trial Financial System), shortening bid preparation time by approximately 30%, quotation turnaround time by approximately 66%, improving monitoring visit compliance by approximately 50% and report preparation efficiency by approximately 25%. The Company's clinical CRO services cover the entire clinical development process, including investigational new drug (IND) applications, Phase I-IV clinical studies, new drug application (NDA) registration filings, as well as FSP services and other services.

The announcement states that the Company's operating efficiency and profitability are both above industry average: in 2025, its gross margin was 38.9% (industry average approximately 30%), net margin 15.4% (industry average approximately 10%), and revenue per employee reached RMB 0.71 million (industry average approximately RMB 0.55 million).

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.